Related Experiment Video
Updated: Jun 21, 2025
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Prevention of Heart Failure in Patients with Chronic Kidney Disease
Amr Raghban1, Jennifer Kirsop2, W H Wilson Tang1,2
1Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk J3-4, Cleveland, OH 44195, USA.
Insights
Patients with chronic kidney disease (CKD) face a high risk of heart failure (HF). Early interventions using biomarkers, lifestyle changes, and specific medications can help prevent HF development and progression in this population.
Area of Science:
- Cardiology
- Nephrology
- Clinical Pharmacology
Background:
- Patients with chronic kidney disease (CKD) exhibit an elevated risk for developing heart failure (HF).
- Limited research has focused on the specific pathophysiologic mechanisms and preventive treatments for HF in CKD patients.
- Identifying individuals at high risk is crucial for timely intervention.
Purpose of the Study:
- To review the pathophysiologic links between CKD and HF.
- To explore diagnostic biomarkers for risk stratification.
- To evaluate current and potential therapeutic strategies for HF prevention in CKD.
Main Methods:
- Literature review of clinical studies and guidelines.
- Analysis of data on cardiac and renal biomarkers.
- Evaluation of evidence for pharmacological interventions.
Main Results:
- Clinically available biomarkers can identify CKD patients at risk for HF.
- Dietary and lifestyle modifications (exercise, smoking cessation) are recommended.
- Risk factor control (blood pressure, glucose, lipids) is essential.
- Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers show consistent risk reduction.
- Beta-blockers and mineralocorticoid receptor antagonists show promise but lack large-scale trial evidence for HF prevention in CKD.
Conclusions:
- CKD poses a significant risk for HF development.
- A multi-faceted approach including biomarkers, lifestyle changes, and targeted pharmacotherapy is necessary for HF prevention in CKD.
- Further clinical trials are needed to establish the role of certain HF medications in this population.
Abstract:
Patients with chronic kidney disease (CKD) have heightened risk of developing heart failure (HF), yet few clinical studies have directly investigated the pathophysiologic underpinnings or therapeutic strategies to prevent HF. A wide range of clinically available cardiac and renal biomarkers can identify at-risk individuals who would benefit from dietary and lifestyle modifications (exercise prescription, smoking cessation), as well as risk factor modification (blood pressure, glucose, and lipid control). Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have the most consistent data for risk reduction, while other standard HF drugs such as beta-blockers and mineralocorticoid receptor antagonists have promising findings but no large-scale clinical trial evidence for their routine use to prevent the development and progression of HF in this vulnerable population.
Related Concept Videos
01:22Heart Failure Drugs: Diuretics
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Heart Failure Drugs: β-Blockers
01:17Pathophysiology of Heart Failure
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:27Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...